Paul Tudor Jones II: 32 Vertex Pharmaceuticals transactions (Tudor

32 Paul Tudor Jones II Vertex Pharmaceuticals Trades

Paul Tudor Jones II acquired 9.46 Thousand Vertex Pharmaceuticals shares worth $4.02 Million. That's 0.05% of their equity portfolio (459th largest holding). The first Vertex Pharmaceuticals trade was made in Q2 2014. Since then Paul Tudor Jones II bought shares fourteen more times and sold shares on nineteen occasions. The investor's estimated purchase price is $4.36 Million, resulting in a loss of 7.8%.

Avg closing price

Price range

New holding (+9.46 Thousand shares) Q4 2024

Avg closing price $461.09

Price range $397.27 - $516.74

Sold -23.5 Thousand shares Q2 2024

Avg closing price $434.05

Price range $392.81 - $485.53

Sold 10.9% shares (-2.88 Thousand shares) Q1 2024

Avg closing price $422.74

Price range $407.69 - $446.08

Sold 20.8% shares (-6.95 Thousand shares) Q4 2023

Avg closing price $369.42

Price range $343.00 - $410.68

New holding (+33.4 Thousand shares) Q3 2023

Avg closing price $349.73

Price range $338.18 - $362.46

Sold -7.58 Thousand shares Q1 2023

Avg closing price $299.93

Price range $283.23 - $323.10

New holding (+7.58 Thousand shares) Q4 2022

Avg closing price $304.77

Price range $285.76 - $321.48

Sold -29.7 Thousand shares Q4 2021

Avg closing price $194.45

Price range $177.01 - $223.45

New holding (+29.7 Thousand shares) Q3 2021

Avg closing price $195.24

Price range $181.39 - $202.99

Sold -17.3 Thousand shares Q2 2021

Avg closing price $209.17

Price range $187.49 - $221.10

Sold 62.7% shares (-29 Thousand shares) Q1 2021

Avg closing price $219.65

Price range $207.02 - $241.31

Increased shares by 711.9% (+40.6 Thousand shares) Q4 2020

Avg closing price $229.44

Price range $207.01 - $276.09

Sold 26.8% shares (-2.08 Thousand shares) Q3 2020

Avg closing price $275.88

Price range $255.65 - $303.10

Sold 24.9% shares (-2.59 Thousand shares) Q2 2020

Avg closing price $271.12

Price range $225.48 - $295.80

Sold 33.7% shares (-5.28 Thousand shares) Q1 2020

Avg closing price $229.39

Price range $199.77 - $247.81

New holding (+15.6 Thousand shares) Q4 2019

Avg closing price $202.38

Price range $166.71 - $223.91

Sold -6.36 Thousand shares Q1 2019

Avg closing price $184.70

Price range $163.73 - $194.70

Sold 23.4% shares (-1.94 Thousand shares) Q4 2018

Avg closing price $173.27

Price range $151.91 - $192.21

Sold 52.8% shares (-9.29 Thousand shares) Q3 2018

Avg closing price $178.07

Price range $167.73 - $192.74

Increased shares by 623.5% (+15.2 Thousand shares) Q2 2018

Avg closing price $155.01

Price range $145.72 - $169.96

News about Vertex Pharmaceuticals, Inc. and Paul Tudor Jones II

VRTX Down as Non-Opioid Drug Shows Similar Pain Reduction as Placebo

Vertex announces data from a phase II study evaluating its NaV1.8 pain signal inhibitor, suzetrigine, for treating painful lumbosacral radiculopathy. Shares ...

zacks.com, 5 months ago

Insider Sell: EVP, Chief Technical Ops. Off. ...

Insider Sell: EVP, Chief Technical Ops. Off. Atkinson Edward Morrow III Sells Shares of Vertex Pharmaceuticals Inc

GuruFocus, about 1 year ago

3 Tech Stocks to Watch for Groundbreaking Innovations in 2030

It’s an understatement to say that the pace of technology is rapidly changing. That was apparent in my research for this article. Specifically, I looked at s...

InvestorPlace, almost 2 years ago